BMI shouldn’t be the only way to assess who can access weight-loss drugs
Antonio_Diaz/Getty Images Around one in three Australian adults (32%) has a body-mass index (BMI) of 30 or above. A further 34% has a BMI of 25 or above. Australia’s regulator has approved Wegovy, the weight-loss version of Ozempic (semaglutide) and Mounjaro (tirzepatide) for weight management, alongside a reduced-calorie diet and exercise. To access these medications, […]
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve
AstraZeneca AZN recently signed a landmark agreement with the Trump administration to lower drug prices in the United States. The announcement comes just days after Pfizer PFE signed a similar deal with the government. Like Pfizer, AstraZeneca has agreed to reduce the prices of its prescription drugs to match those in comparable developed countries, supporting President Trump’s […]
This Popular Skin-Tightening Procedure In South Korea Is Now Available To Americans
Traditional radiofrequency devices have long been dogged by compromises—painful sessions, unwanted fat loss, a major drawback particularly in the GLP-1 era, or results that fade too fast. Cynosure Lutronic’s XERF system, cleared by the United States Food and Drug Administration in August and already popular in South Korea, pledges to … The post This Popular […]
How Do GLP-1 Drugs Stack Up for Cardiorenal Benefits in Diabetes?
(MedPage Today) — Three GLP-1 receptor agonists had generally comparable cardiorenal outcomes when used in type 2 diabetes, a retrospective comparative effectiveness study indicated. Among 21,790 military veterans with diabetes, initiators of…
Numerator launches GLP-1 Trends Hub to track retail impact of weight loss drugs
Early findings highlight long-term influence of GLP-1s on consumer behavior
If You Invested $1000 in McKesson a Decade Ago, This is How Much It’d Be Worth Now
How much a stock’s price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries. Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing […]
Coca-Cola brings new innovation to convenience stores
Many consumers prefer convenience stores over all the other alternatives, even for their regular grocery shopping. Why? It’s simple: They have a strong presence nationwide and offer easy access and a fast shopping experience for essential products. Convenience stores also operate more extended hours, allowing for even more conveniences (pardon the pun). As these stores […]
Down 44%, Should You Buy the Dip on Viking Therapeutics?
Key Points Viking Therapeutics is nearing the finish line with a candidate for weight loss — to potentially enter a drug market that’s approaching $100 billion. This biotech has candidates in phase 2 and phase 3 trials, and data so far are promising. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: […]
Collaborate or die: Hacking the next generation of healthy foods at MISTA
Is fiber finally getting its day in the sun? Is RFK Jr’s anti-seed oil crusade filtering through to consumers? And have we reached peak protein? We may see a falloff in the “faddish worship of protein,” predicted Mintel director, food & drink, Jenny Zegler at the third MISTA growth hack demo day in San Francisco […]
Ascletis selects ASC-35 as clinical development candidate
Ascletis Pharma Inc. has selected ASC-35, a once-monthly, subcutaneously administered GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual peptide agonist, as a clinical development candidate. Ascletis expects to submit an IND application to the FDA for ASC-35 for the treatment of obesity in the second quarter of next year.